At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.
To kick off the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, noted 6 major trends in the 2023 specialty therapy pipeline:
Tancredi noted that specialty pharmacies grew by 315% between 2015 and 2021, with hospital or health system-owned specialty pharmacies accounting for about a third of this total growth—and that the specialty drug pipeline is projected to grow by another 8% each year through 2025.
“Specialty pharmacy continues to carry the FDA pipeline year over year,” Tancredi said. “What I saw was about 39 more drugs that could potentially be approved by the end of 2023, and of those 39, I think 28 of them could be considered specialty.”
He first listed 8 major recent specialty drug approvals that “have the potential to change the standard of care in a given disease and/or have a large economic impact to payer.” These were:
Looking to the rest of 2023, there are several more specialty drugs anticipated to receive FDA approval. Here is a wrapped-up version of these anticipated approvals.
Rare and Orphan Disease
Tancredi focused on 23 drugs in the pipeline to treat a large variety of rare and orphan diseases. There are more than 7000 rare diseases, which affect fewer than 200,000 individuals per condition and 30 million Americans overall. Since the Orphan Drug Act was signed into law in 1983, the FDA has approved hundreds of treatments for rare diseases, though most rare diseases still do not have FDA-approved treatments.
This list included 11 oral drugs and 12 drugs delivered via injection. All drugs are in phase 2 or 3 of research and development, or filed for FDA approval.
The orally administrated drugs on this list include:
The drugs delivered via injection on this list include:
Specialty Drugs
Tancredi focused on 19 traditional specialty drugs in the pipeline for FDA approval, including 10 oral drugs, 8 drugs delivered via injection, and 1 delivered via inhalation.
The orally-administrated drugs on this list include:
The drugs delivered via injection on this list include:
Additionally, treprostinil sodium was the only drug on this list delivered via inhalation.
Oncology
Tancredi noted that about 13 oncology drugs are approved each year. In 2023, there are 16 oral drugs and 6 drugs delivered via injection in the pipeline, with 6 drugs in the pipeline for breast cancer and 3 for non-small cell lung cancer (NSCLC).
The orally-administrated drugs on this list include:
The drugs delivered via injection on this list include:
Gene and Cell Therapies
There are 13 injectable gene and cell therapies in the pipeline, with 1 drug delivered topically.
The gene and cell therapies delivered via injection on this list include:
Beremagene geperpavec is also in the pipeline for topical treatment of dystrophic epidermolysis bullosa.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More